(Q36276017)
Statements
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia (English)
Thomas J Kipps
Herbert Eradat
John Catalano
Walter Cosolo
Iryna S Dyagil
Sreeni Yalamanchili
Akiko Chai
Srikumar Sahasranaman
Elizabeth Punnoose
Deborah Hurst
1 reference